Newcombe, A. A., Gibson, B. E.S. and Keeshan, K. (2018) Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 63, pp. 1-11. (doi: 10.1016/j.exphem.2018.03.008) (PMID:29608923)
|
Text
159845.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 719kB |
Abstract
There is a desperate need for new and effective therapeutic approaches for AML in both children and adults. Epigenetic aberrations are common in adult AML, and many novel epigenetic compounds are in clinical development that may improve patient outcomes. Mutations in epigenetic regulators occur less frequently in AML in children compared to adults. However, investigating the potential benefits of epigenetic therapy in paediatric AML is an important issue that will be discussed in this review.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Keeshan, Dr Karen and Gibson, Professor Brenda and Newcombe, Ashley |
| Authors: | Newcombe, A. A., Gibson, B. E.S., and Keeshan, K. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Experimental Hematology |
| Publisher: | Elsevier |
| ISSN: | 0301-472X |
| ISSN (Online): | 1873-2399 |
| Published Online: | 30 March 2018 |
| Copyright Holders: | Copyright © 2018 ISEH – Society for Hematology and Stem Cells |
| First Published: | First published in Experimental Hematology 63: 1-11 |
| Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details